BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 29302806)

  • 21. BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management.
    Lindor NM; Goldgar DE; Tavtigian SV; Plon SE; Couch FJ
    Oncologist; 2013; 18(5):518-24. PubMed ID: 23615697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
    Cotrim DP; Ribeiro ARG; Paixão D; de Queiroz Soares DC; Jbili R; Pandolfi NC; Cezana C; de Cássia Mauro C; Mantoan H; Bovolim G; de Brot L; Torrezan GT; Carraro DM; Baiocchi G; da Cruz Formiga MN; da Costa AABA
    BMC Cancer; 2019 Jan; 19(1):4. PubMed ID: 30606148
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Concolino P; Gelli G; Rizza R; Costella A; Scambia G; Capoluongo E
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort.
    Jarhelle E; Riise Stensland HM; Mæhle L; Van Ghelue M
    Fam Cancer; 2017 Jan; 16(1):1-16. PubMed ID: 27495310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
    Campos B; Díez O; Domènech M; Baena M; Balmaña J; Sanz J; Ramírez A; Alonso C; Baiget M
    Hum Mutat; 2003 Oct; 22(4):337. PubMed ID: 12955719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).
    Tokunaga H; Iida K; Hozawa A; Ogishima S; Watanabe Y; Shigeta S; Shimada M; Yamaguchi-Kabata Y; Tadaka S; Katsuoka F; Ito S; Kumada K; Hamanaka Y; Fuse N; Kinoshita K; Yamamoto M; Yaegashi N; Yasuda J
    PLoS One; 2021; 16(1):e0236907. PubMed ID: 33428613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Next step in molecular genetics of hereditary breast/ovarian cancer: Multigene panel testing in clinical actionably genes and prioritization algorithms in the study of variants of uncertain significance.
    Castillo-Guardiola V; Rosado-Jiménez L; Sarabia-Meseguer MD; Marín-Vera M; Macías-Cerrolaza JA; García-Hernández R; Zafra-Poves M; Sánchez-Henarejos P; Moreno-Locubiche MÁ; Cuevas-Tortosa E; Arnaldos-Carrillo M; Ayala de la Peña F; Alonso-Romero JL; Noguera-Velasco JA; Ruiz-Espejo F
    Eur J Med Genet; 2022 Apr; 65(4):104468. PubMed ID: 35245693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients.
    Sanz DJ; Acedo A; Infante M; Durán M; Pérez-Cabornero L; Esteban-Cardeñosa E; Lastra E; Pagani F; Miner C; Velasco EA
    Clin Cancer Res; 2010 Mar; 16(6):1957-67. PubMed ID: 20215541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variants of uncertain significance in BRCA1 and BRCA2 assessment of in silico analysis and a proposal for communication in genetic counselling.
    Moghadasi S; Hofland N; Wouts JN; Hogervorst FB; Wijnen JT; Vreeswijk MP; van Asperen CJ
    J Med Genet; 2013 Feb; 50(2):74-9. PubMed ID: 23231788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variant classification changes over time in BRCA1 and BRCA2.
    Mighton C; Charames GS; Wang M; Zakoor KR; Wong A; Shickh S; Watkins N; Lebo MS; Bombard Y; Lerner-Ellis J
    Genet Med; 2019 Oct; 21(10):2248-2254. PubMed ID: 30971832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany.
    Meyer P; Voigtlaender T; Bartram CR; Klaes R
    Hum Mutat; 2003 Sep; 22(3):259. PubMed ID: 12938098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay.
    Hu C; Susswein LR; Roberts ME; Yang H; Marshall ML; Hiraki S; Berkofsky-Fessler W; Gupta S; Shen W; Dunn CA; Huang H; Na J; Domchek SM; Yadav S; Monteiro ANA; Polley EC; Hart SN; Hruska KS; Couch FJ
    Clin Cancer Res; 2022 Sep; 28(17):3742-3751. PubMed ID: 35736817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Next-generation sequencing of the BRCA1 and BRCA2 genes for the genetic diagnostics of hereditary breast and/or ovarian cancer.
    Trujillano D; Weiss ME; Schneider J; Köster J; Papachristos EB; Saviouk V; Zakharkina T; Nahavandi N; Kovacevic L; Rolfs A
    J Mol Diagn; 2015 Mar; 17(2):162-70. PubMed ID: 25556971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRCA1 Norway: comparison of classification for BRCA1 germline variants detected in families with suspected hereditary breast and ovarian cancer between different laboratories.
    Hovland HN; Al-Adhami R; Ariansen SL; Van Ghelue M; Sjursen W; Lima S; Bolstad M; Berger AH; Høberg-Vetti H; Knappskog P; Haukanes BI; Aukrust I; Ognedal E
    Fam Cancer; 2022 Oct; 21(4):389-398. PubMed ID: 34981296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative analysis of BRCA1 and BRCA2 variants of uncertain significance in patients with breast cancer: a multifactorial probability-based model versus ACMG standards and guidelines for interpreting sequence variants.
    Park KS; Cho EY; Nam SJ; Ki CS; Kim JW
    Genet Med; 2016 Dec; 18(12):1250-1257. PubMed ID: 27124784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes.
    Billaud A; Chevalier LM; Augereau P; Frenel JS; Passot C; Campone M; Morel A
    Genome Med; 2021 Nov; 13(1):174. PubMed ID: 34749799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition.
    Dos Santos ES; Caputo SM; Castera L; Gendrot M; Briaux A; Breault M; Krieger S; Rogan PK; Mucaki EJ; Burke LJ; ; Bièche I; Houdayer C; Vaur D; Stoppa-Lyonnet D; Brown MA; Lallemand F; Rouleau E
    Breast Cancer Res Treat; 2018 Apr; 168(2):311-325. PubMed ID: 29236234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of Heterozygosity in BRCA1 and BRCA2 Genes in Patients with Ovarian Cancer and Probability of Its Use for Clinical Classification of Variations.
    Kechin AA; Boyarskikh UA; Ermolenko NA; Tyulyandina AS; Lazareva DG; Avdalyan AM; Tyulyandin SA; Kushlinskii NE; Filipenko ML
    Bull Exp Biol Med; 2018 May; 165(1):94-100. PubMed ID: 29797126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of BRCA1/2 variants of unknown significance in the prospective Korean Hereditary Breast Cancer study.
    Kim JH; Park S; Park HS; Park JS; Lee ST; Kim SW; Lee JW; Lee MH; Park SK; Noh WC; Choi DH; Han W; Jung SH
    Sci Rep; 2021 Apr; 11(1):8485. PubMed ID: 33875706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.